How should I assess and manage headaches that occur with stimulant (e.g., amphetamine, methylphenidate, cocaine, MDMA, nicotine) use?

Assessment and Management of Stimulant-Associated Headaches

Immediate Assessment Priorities

First, determine whether the headache represents a primary headache disorder triggered or exacerbated by stimulants versus a secondary headache caused by stimulant-induced vascular complications.

Critical Red-Flag Features Requiring Urgent Neuroimaging

• Thunderclap onset (sudden, severe headache reaching maximum intensity within seconds to minutes) suggests reversible cerebral vasoconstriction syndrome (RCVS), subarachnoid hemorrhage, or acute hypertensive crisis—all well-documented complications of cocaine, amphetamines, and MDMA. 1
• Progressive worsening pattern over days to weeks, particularly with cocaine or methamphetamine use, may indicate evolving intracranial hemorrhage, aneurysmal formation, or ischemic stroke. 2
• New focal neurological deficits (weakness, sensory changes, visual field cuts, ataxia) mandate immediate MRI with and without contrast to exclude hemorrhagic or ischemic stroke. 1
• Altered mental status, seizure, or impaired consciousness requires emergent CT followed by MRI and consideration of toxicology screening. 1

Stimulant-Specific Vascular Complications

• Cocaine causes vasoconstriction through sympathetic nervous system stimulation and impaired reuptake of epinephrine, norepinephrine, serotonin, and dopamine; RCVS occurs most commonly in middle-aged adults and females. 2
• Cocaine-related headaches may occur immediately after use, within 40–90 minutes of a binge, or even after prolonged abstinence, reflecting different mechanisms (acute sympathomimetic effects versus serotonergic system alterations during withdrawal). 2, 3
• Amphetamines and methylphenidate produce similar sympathomimetic effects and can trigger RCVS, hypertensive crisis, and intracranial hemorrhage, particularly at higher doses or with concurrent use of other stimulants. 4
• MDMA releases serotonin, dopamine, and norepinephrine; combined use with methylphenidate significantly increases cardiovascular and adverse effects without enhancing psychotropic benefits. 4

---

Acute Treatment Algorithm for Stimulant-Associated Headaches

Step 1: Rule Out Secondary Causes

• Obtain blood pressure measurement immediately; uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥120 mmHg) contraindicates NSAIDs and triptans and requires urgent blood pressure management before headache treatment. 1
• If red-flag features are present, obtain MRI brain with and without contrast (preferred) or CT head without contrast if MRI is unavailable. 1
• For cocaine users with acute severe headache, consider CT angiography or MR angiography to evaluate for RCVS, aneurysm, or arterial dissection. 2

Step 2: First-Line Acute Treatment (Assuming No Red Flags and Controlled Blood Pressure)

For mild-to-moderate headaches:

• NSAIDs are first-line therapy: ibuprofen 400–800 mg, naproxen sodium 500–825 mg, or aspirin 1000 mg at headache onset. 5, 6
• Acetaminophen 1000 mg is the safest alternative when NSAIDs are contraindicated (e.g., uncontrolled hypertension, renal impairment, GI bleeding risk). 1
• Adding caffeine 100–200 mg with the NSAID provides synergistic analgesia, though total daily caffeine intake must be monitored as it may worsen stimulant-related side effects (tachycardia, anxiety, insomnia). 6

For moderate-to-severe headaches or NSAID failure:

• Triptans are contraindicated within 24 hours of cocaine, amphetamine, or MDMA use due to additive vasoconstriction and risk of myocardial infarction, stroke, or RCVS. 1, 2
• Once stimulant effects have fully resolved (typically ≥24–48 hours after last use), triptans may be considered if cardiovascular risk factors are absent: sumatriptan 50–100 mg, rizatriptan 10 mg, or eletriptan 40 mg. 5
• Metoclopramide 10 mg IV or prochlorperazine 10 mg IV provides direct analgesic effects through central dopamine receptor antagonism and is safe in the acute setting when triptans are contraindicated. 1, 7

Step 3: Medications to Absolutely Avoid

• Opioids (codeine, hydromorphone, oxycodone) and butalbital-containing compounds should never be used for stimulant-associated headaches due to limited efficacy, high risk of medication-overuse headache, potential for dependency, and lack of evidence supporting their use in this population. 5, 1
• Ergotamine and dihydroergotamine (DHE) are contraindicated within 24 hours of stimulant use due to additive vasoconstrictive effects and risk of ischemic complications. 1

Step 4: Frequency Limits to Prevent Medication-Overuse Headache

• Limit all acute headache medications to ≤2 days per week (≤10 days per month) to prevent medication-overuse headache, which can paradoxically increase headache frequency and lead to daily headaches. 5, 1, 6
• If headaches occur more than twice weekly despite acute treatment, initiate preventive therapy immediately rather than increasing acute medication frequency. 6

---

Preventive Therapy for Recurrent Stimulant-Associated Headaches

Indications for Preventive Therapy

• ≥2 headache attacks per month producing disability lasting ≥3 days. 1
• Acute medication use >2 days per week. 1, 6
• Contraindication to or failure of acute therapies. 1
• Patient preference for a preventive approach. 1

First-Line Preventive Options

• Propranolol 80–240 mg/day or timolol 20–30 mg/day are first-line beta-blockers with strong evidence for migraine prevention, though propranolol may worsen ADHD symptoms in patients on therapeutic stimulants (Adderall, methylphenidate). 6, 7
• Amitriptyline 30–150 mg/day is preferred when patients have comorbid depression, anxiety, or sleep disturbances and is superior for mixed migraine plus tension-type headache. 1, 7
• Topiramate 50–200 mg/day is an alternative first-line option with proven efficacy in chronic migraine. 7

Second-Line and Third-Line Options

• CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) should be considered when oral preventives fail, with efficacy assessed after 3–6 months. 7
• OnabotulinumtoxinA (Botox) is FDA-approved for chronic migraine (≥15 headache days per month) and should be used when three oral preventives have failed; the recommended protocol is 155–195 units injected across 31–39 sites every 12 weeks, with efficacy evaluated after 6–9 months. 1

---

Management of Medication-Overuse Headache in Stimulant Users

Recognition and Diagnosis

• Daily or near-daily headaches in a patient using acute medications (NSAIDs, triptans, acetaminophen) ≥15 days/month (or triptans/combination analgesics ≥10 days/month) for >3 months indicate medication-overuse headache. 1
• Concurrent daily stimulant use (therapeutic or recreational) plus daily acute headache medication creates a self-perpetuating cycle that sustains chronic headache. 1

Immediate Withdrawal Protocol

• Abrupt cessation of all overused acute medications is recommended; evidence does not support gradual taper. 1
• Patients should be warned that headache intensity may temporarily worsen for 2–10 days during withdrawal. 1
• Substituting another acute medication during withdrawal is discouraged because it merely transfers overuse to a different agent. 1

Post-Withdrawal Management

• Once medication-overuse headache resolves (typically 2–4 weeks after discontinuation), acute treatment should be reserved for the most severe, disabling attacks and limited to ≤2 days per week. 1
• Initiate preventive therapy immediately during or after withdrawal to break the cycle of frequent attacks. 1, 7

---

Special Considerations for Specific Stimulants

Therapeutic Stimulants (Adderall, Methylphenidate, Wellbutrin)

• Headaches occurring in patients on Wellbutrin (bupropion) plus Adderall are most commonly related to additive stimulant properties; afternoon headaches suggest peak-dose effects. 6
• First-line acute treatment: ibuprofen 400–600 mg or naproxen sodium 500 mg at headache onset, with optional caffeine 100–200 mg for synergistic effect (monitor total daily caffeine). 6
• If headaches occur >2 days per week, initiate preventive therapy (propranolol 80–240 mg/day or amitriptyline 30–150 mg/day) rather than relying solely on acute treatments. 6

Cocaine

• Immediate-onset headaches (within minutes) reflect acute sympathomimetic and vasoconstrictive effects. 2, 3
• Delayed headaches (40–90 minutes after a binge) may indicate evolving RCVS or hypertensive crisis. 2, 3
• Withdrawal headaches (hours to days after last use) relate to cocaine-induced serotonergic system alterations. 3
• Triptans and ergots are absolutely contraindicated within 24–48 hours of cocaine use due to additive vasoconstriction. 2

MDMA (Ecstasy)

• MDMA releases serotonin, dopamine, and norepinephrine; headaches may occur during acute intoxication or withdrawal. 4
• Combined use with methylphenidate significantly increases cardiovascular and adverse effects without enhancing psychotropic benefits. 4
• Triptans are contraindicated within 24–48 hours of MDMA use due to serotonergic and vasoconstrictive interactions. 4

Nicotine

• Nicotine withdrawal is a well-recognized cause of headache; gradual tapering or nicotine replacement therapy may reduce withdrawal-related headaches. 8
• Acute nicotine use (smoking, vaping) can trigger migraine attacks in susceptible individuals through vasoconstrictive effects. 8

---

Critical Pitfalls to Avoid

• Do not prescribe triptans or ergots within 24–48 hours of stimulant use (cocaine, amphetamines, MDMA) due to additive vasoconstriction and risk of stroke, myocardial infarction, or RCVS. 1, 2
• Do not allow patients to increase acute medication frequency in response to treatment failure; this creates a vicious cycle of medication-overuse headache. 1, 6
• Do not use opioids or butalbital compounds for stimulant-associated headaches; they have limited efficacy, high risk of dependency, and potential for rebound headaches. 5, 1
• Do not delay preventive therapy while trialing multiple acute strategies; early initiation of prevention is essential for patients with frequent attacks. 1, 6, 7
• Do not assume a normal CT excludes all secondary causes; MRI with and without contrast is required to exclude venous sinus thrombosis, intracranial hypotension, or early mass lesions. 7

---

When to Refer to a Headache Specialist or Neurologist

• Immediate referral is required for onabotulinumtoxinA administration and comprehensive management of refractory chronic migraine. 1
• Urgent referral is indicated when the diagnosis is uncertain, all first-line treatments have failed, or complications (RCVS, stroke, hemorrhage) arise. 1
• Routine referral is appropriate for patients requiring CGRP monoclonal antibodies or advanced preventive strategies. 7